Glucophage Exclusivity Compromise Could Resolve Pediatric Bill Delay
Executive Summary
Democratic House Energy/Commerce Committee staff are considering a provision to assure a defined period of Glucophage exclusivity as a way out of the tie-up on pediatric exclusivity reauthorization legislation
You may also be interested in...
Pediatric Bills' Generic Approval "Carve-Out" Needs Refinement, Hatch Says
Provisions of bills to renew the pediatric exclusivity program which allow for approval of generics despite protected labeling by innovators should be revised, Sen. Orrin Hatch (R-Utah) said.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials